Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - fentanyl, quantity: 4.2 mg - drug delivery system, transdermal - excipient ingredients: polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; 2,2'-azobisisobutyronitrile; 2-hydroxyethyl acrylate - for the management of pain associated with cancer, palliative cancer and other conditions in patients where: - other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and - the pain is opioid-responsive, and - severe enough to require daily, continuous long term opioid treatment. not for use in opioid-naive patients.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - fentanyl, quantity: 12.6 mg - drug delivery system, transdermal - excipient ingredients: polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; 2,2'-azobisisobutyronitrile; 2-hydroxyethyl acrylate - for the management of pain associated with cancer, palliative cancer and other conditions in patients where: - other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and - the pain is opioid-responsive, and - severe enough to require daily, continuous long term opioid treatment. not for use in opioid-naive patients.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - fentanyl -

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - fentanyl, quantity: 2.1 mg - drug delivery system, transdermal - excipient ingredients: polyethylene terephthalate; ethylene/vinyl acetate copolymer; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; 2,2'-azobisisobutyronitrile; 2-hydroxyethyl acrylate - for the management of pain associated with cancer, palliative care, and other conditions in patients where:,? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? severe enough to require daily, continuous, long term opioid treatment. not for use in opioid-na?ve patients.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - diazepam, quantity: 5 mg/ml - injection, solution - excipient ingredients: ethanol; propylene glycol; sodium hydroxide; water for injections - management of anxiety disorders or for the short-term relief of symptoms of anxiety. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. in acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. diazepam is a useful adjunct for the relief of reflex muscle spasms due to local trauma (injury, inflammation) to muscles, bones and joints. it can also be used to combat spasticity due to upper motor neuron lesions such as cerebral palsy and paraplegia, as well as in athetosis and stiff man syndrome. intravenous diazepam is useful in controlling status epilepticus and the spasms of tetatnus. diazepam is also used as preoperative medication.

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - fentanyl, quantity: 16.8 mg - drug delivery system, transdermal - excipient ingredients: polyethylene terephthalate; ethylene/vinyl acetate copolymer; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; 2,2'-azobisisobutyronitrile; 2-hydroxyethyl acrylate - for the management of pain associated with cancer, palliative care, and other conditions in patients where:,? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? severe enough to require daily, continuous, long term opioid treatment. not for use in opioid-na?ve patients.

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - fentanyl, quantity: 12.6 mg - drug delivery system, transdermal - excipient ingredients: polyethylene terephthalate; ethylene/vinyl acetate copolymer; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; 2,2'-azobisisobutyronitrile; 2-hydroxyethyl acrylate - for the management of pain associated with cancer, palliative care, and other conditions in patients where:,? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? severe enough to require daily, continuous, long term opioid treatment. not for use in opioid-na?ve patients.

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - fentanyl, quantity: 8.4 mg - drug delivery system, transdermal - excipient ingredients: ethylene/vinyl acetate copolymer; polyethylene terephthalate; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; 2,2'-azobisisobutyronitrile; 2-hydroxyethyl acrylate - for the management of pain associated with cancer, palliative care, and other conditions in patients where:,? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? severe enough to require daily, continuous, long term opioid treatment. not for use in opioid-na?ve patients.

Australia - English - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - fentanyl, quantity: 4.2 mg - drug delivery system, transdermal - excipient ingredients: polyethylene terephthalate; ethylene/vinyl acetate copolymer; ethyl acetate; 2-ethylhexyl acrylate; vinyl acetate; 2,2'-azobisisobutyronitrile; 2-hydroxyethyl acrylate - for the management of pain associated with cancer, palliative care, and other conditions in patients where:,? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? severe enough to require daily, continuous, long term opioid treatment. not for use in opioid-na?ve patients.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

pfizer ltd - irinotecan hydrochloride trihydrate - solution for infusion - 20mg/1ml